MD-2 Antibody [1A2E3]

Product Specifications

Background

MD-2 Monoclonal Antibody: MD-2 is a member of the Toll/interleukin-1 receptor (TIR) family, a group of proteins that include the Toll-like receptors (TLRs) . TLRs are signaling molecules that recognize different pathogen-associated molecular patterns (PAMPs) and serve as an important link between the innate and adaptive immune responses. TLR4, the major signaling receptor for lipopolysaccharide (LPS), requires the binding of MD-2 to its extracellular region for maximal response to LPS. The specificity of this response is determined by the species of MD-2; e.g., human MD-2 transfected into mouse cells can cause mouse TLR4 to react to LPS analogs that are normally antagonistic to human but not mouse TLR4.

NCBI Gene ID

23643

Swiss Prot

Q9Y6Y9

Accession Number

NP_056179

Host

Mouse

Reactivity

Human, Mouse, Rat

Immunogen

Mouse monoclonal MD-2 antibody was raised against a recombinant protein corresponding to amino acids 2 to 160 of human MD-2.

Clonality

Monoclonal

Clone

1A2E3

Conjugation

Unconjugated

Type

Primary Antibodies

Field of Research

Innate Immunity

Purification

MD-2 Monoclonal Antibody is Protein A purified.

Positive Control

Cat. No. 95-108 - MD-2 Recombinant Protein

Concentration

1 mg/mL

Buffer

MD-2 Monoclonal Antibody is supplied in PBS containing 0.02% sodium azide.

Modification

None

Shipping Conditions

Blue Ice

Storage Conditions

MD-2 monoclonal antibody can be stored at -20˚ C, stable for one year.

Fragment

IgG1

Symbol

LY96

Positive Control 2

Cat. No. 10-901 - Human Spleen Tissue Slide

NCBI Official Name

Lymphocyte antigen 96

NCBI Organism

Homo sapiens

Background Reference 01

O'Neill LAJ, Fitzgerald FA, and Bowie AG. The Toll-IL-1 receptor adaptor family grows to five members. Trends in Imm. 2003; 24:286-9.

Background Reference 02

Vogel SN, Fitzgerald KA, and Fenton MJ. TLRs: differential adapter utilization by toll-like receptors mediates TLR-specific patterns of gene expression. Mol. Interv. 2003; 3:466-77.